IQ Therapeutics completes phase 1 clinical trial of anthrax antibody

IQ Therapeutics has successfully completed the dosing of IQNLF, a fully human antibody against inhalation anthrax, in a phase 1 clinical trial.

The trial included 36 healthy volunteers who participated in the randomized, placebo controlled, double blind, single dose-escalating study, intended to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of IQNLF, reports.

Inhalation anthrax is the most lethal form of anthrax. It currently has limited treatment options, especially for the advanced stage of the infectious disease.

Developed by IQ Therapeutics, a human antibody technology company, IQNLF is one half of a dual antibody treatment of inhalation anthrax, reports. In conjunction with the antibody IQNPA, it forms IQ-DAA, which has shown to be highly effective in pre-clinical animal studies.

“The outcome of the clinical study will provide more insight in the safety of IQNLF and how well the antibody is accepted by the human body at levels that are projected to be efficacious,” Dr. Roland Lageveen, CEO of IQ Therapeutics, said, according to

The Netherlands-based company developed IQNLF and IQNPA by using its patented Cloning the Human Response technology, an advanced technology that generates fully mature human antibodies from immunized donors.

In addition to fighting anthrax, IQ Therapeutics utilizes its unique technology to develop treatments for biodefense, infectious diseases and oncology.